Dr Reddy’s Laboratories Ltd has entered into a multi-country supply and licensing agreement with PanTheryx Inc, the US-based medical nutrition company, granting Dr Reddy’s the exclusive right to market and distribute PanTheryx’s nutritional intervention, DiaResQ, for infectious diarrhoea in India and Nepal and in process for Russia, Myanmar, Vietnam, Ukraine, Sri Lanka, Kazakhstan, Belarus, Jamaica, and select LATAM markets. Dr Reddy’s will market the product in India and Nepal under the Reliqua brand.
G V Prasad, co-chairman and CEO, Dr Reddy’s, stated “This innovative product will address a significant unmet need in the area of diarrhoea. By adding Reliqua to our existing portfolio of gastrointestinal brands, Dr Reddy’s can provide an important new tool for healthcare practitioners across the many markets we serve. Our agreement with PanTheryx is another step towards ensuring good health can be delivered to those who need it.”
DiaResQ helps promote intestinal repair and boost natural immune defenses, resulting in the restoration of normal digestive function. The product was recently recognised in Reimagining Global Health as one of the 30 leading healthcare innovations with great promise to transform global health by 2030.
More From This Section
Infectious diarrhoea is a major world health challenge. Globally, approximately 1.7 billion cases occur annually in children under five. Almost 760,000 of these children under five die every year as a result of this condition. Paediatric infectious diarrhea kills nearly as many children as HIV/AIDS, malaria and measles combined, according to World Health Organization.